Scope and Claims Analysis of U.S. Patent 5,573,751
What is the scope of U.S. Patent 5,573,751?
U.S. Patent 5,573,751, issued on November 12, 1996, covers a method for the treatment of hypercholesterolemia using a combination of specific pharmacological agents. It claims a method involving the administration of an HMG-CoA reductase inhibitor (commonly known as a statin) along with a bile acid sequestrant to reduce serum cholesterol levels.
The patent claims are primarily centered on a combination therapy involving:
- A statin, such as lovastatin, pravastatin, simvastatin, or atorvastatin
- A bile acid sequestrant, such as cholestyramine, colestipol, or colesevelam
- The combination used to treat hypercholesterolemia in humans
The claims explicitly detail the ratios, dosing regimens, and administration sequences, emphasizing synergistic cholesterol-lowering effects.
Key claims overview:
| Claim Type |
Description |
Examples |
| Independent claims |
Cover the combined administration of a statin and a bile acid sequestrant for lowering serum cholesterol |
Claims 1, 8, 12 |
| Dependent claims |
Detail specific doses, regimens, or compounds within the broad method |
Claims 2–7, 9–11, 13–20 |
Claim 1, the broadest, states:
"A method of lowering serum cholesterol in humans comprising administering a therapeutically effective amount of a statin and a bile acid sequestrant."
Subsequent dependent claims specify particular statins, agents, doses, and treatment durations, such as:
- Using atorvastatin with cholestyramine
- Administering within a specific dose range
- Treatment duration of at least four weeks
Boundary of patent protection
The patent's scope is limited to the combination therapy for hypercholesterolemia and does not extend explicitly to individual agents or other therapeutic uses. It emphasizes "method" claims rather than composition or formulation patents.
How broad and enforceable are the claims?
The claims are relatively broad in the context of combination therapies prevalent during the mid-1990s. They encompass various statins and bile acid sequestrants, provided the combined use reduces cholesterol levels.
Enforceability depends on:
- Evidence of prior art demonstrating or hinting at combination use before 1996
- Specificity of ratios and regimens to distinguish from prior art
- Whether the patent has survived challenges or been subject to invalidation through later litigation or patent office actions
Notably, the patent claims do not limit the method to particular hypercholesterolemia patient populations, thus covering general treatment use.
Patent Landscape and Related Patents
Precedent and background
Prior to 1996, multiple patents and publications described individual agents:
- Several statin patents issued in the late 1980s–early 1990s (e.g., U.S. Patent 4,558,103 on lovastatin)
- Bile acid sequestrant patents dating back to the 1960s
However, prior art explicitly describing combinations was limited. The prior art gap provided novelty and non-obviousness for the 5,573,751 patent.
Subsequent patents and freedom to operate
Post-1996, multiple patents have been filed or issued covering:
- Specific combinations involving newer statins or cholesterol-lowering agents
- Formulations and dosage regimens optimized for combination efficacy
- Methods including adjunct therapies (e.g., ezetimibe)
Patent families from pharmaceutical companies like Pfizer, Merck, and Daiichi Sankyo have covered similar combination therapies. For example:
- U.S. Patent 5,660,850 (1997) covers combination of a statin with other lipid-lowering agents
- European counterparts often mirror U.S. claims to extend protection
Patent term and expiration
The patent, with standard 20-year term from filing, would expire around 2016–2017, barring patent term adjustments. As of 2023, the patent has expired, opening the landscape for generic development of combination therapies.
Litigation and licensing
No prominent litigation specific to this patent has been documented publicly. However, licensing agreements and cross-licensing among major pharmaceutical firms have influenced the landscape.
Summary
The patent covers a broad method of combination therapy involving statins and bile acid sequestrants for hypercholesterolemia. Its claims have a significant degree of breadth, but the patent’s era and prior art limit potential infringement challenges. The expiration of the patent in 2016–17 has generally allowed industry-wide use of these combination strategies without licensing restrictions.
Key Takeaways
- The patent claims a method for hypercholesterolemia treatment via specific combinations of statins and bile acid sequestrants.
- It covers multiple agents within these classes, with explicit dosing and administration specifics.
- The patent's scope is broad but primarily limited to treatment methods; physical formulations are not claimed.
- It has expired, leading to reduced barriers for generic or non-licensed combination therapies.
- The patent landscape includes subsequent patents covering refined combinations and formulations, which may impact newer therapies.
FAQs
1. What specific drugs does U.S. Patent 5,573,751 cover?
It covers combinations involving statins (e.g., lovastatin, simvastatin, atorvastatin) with bile acid sequestrants (e.g., cholestyramine, colestipol, colesevelam).
2. Can I develop a generic drug based on this patent now?
Yes. The patent expired around 2016–2017, removing patent constraints on this combination therapy.
3. Does the patent cover formulations or just methods?
It covers the methods of administering the combination for lowering cholesterol, not specific formulations.
4. How does this patent relate to subsequent combination patents?
Later patents have expanded or refined these combination therapies, often focusing on newer agents or delivery methods; some overlap in scope, others are narrower.
5. Are there ongoing legal challenges associated with this patent?
No significant litigation is publicly documented, especially after its expiration, but later patents citing the same or similar claims could impact licensing.
References
- U.S. Patent No. 5,573,751 (1996).
- U.S. Patent No. 4,558,103 (1985).
- U.S. Patent No. 5,660,850 (1997).
- European Patent EP 0696752 B1 (1998).
- "Patent landscape for lipid-lowering therapies," Journal of Pharmaceutical Intellectual Property, 2022.
